Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
1999-07-29
2002-04-30
Brusca, John S. (Department: 1631)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C530S350000
Reexamination Certificate
active
06379923
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to newly identified polynucleotides, polypeptides encoded by them and to the use of such polynucleotides and polypeptides, and to their production. More particularly, the polynucleotides and polypeptides of the present invention relate to a new member of an ELL family of RNA polymerase II elongation factors, hereinafter referred to as ELL2. The invention also relates to inhibiting or activating the action of such polynucleotides and polypeptides.
BACKGROUND OF THE INVENTION
The elongation stage of eukaryotic messenger RNA synthesis is a major site for the regulation of gene expression (Reines, D. et al.,
Trends. Biochem. Sci
. 21:351-355 (1996), Bentley, D. L.,
Curr. Opin. Genet. Dev
. 5:210-216 (1995)). Moreover, a growing body of evidence suggests that mis-regulation of elongation may be a key element in a variety of human diseases (Aso, T. et al.,
J. Clin. Invest
. 97:1561-1569 (1996)).
To date, one virally encoded protein (Tat) and five cellular proteins (SII, P-TEFb, TFIIF, Elongin (SIII), and ELL) have been defined biochemically and shown to be capable of controlling the activity of the RNA polymerase II elongation complex. Among these elongation factors, three have been implicated in human disease. The HIV-1 encoded Tat protein is required for efficient transcription of HIV-1 genes and for productive infection by the virus (Jones, K. A. & Peterlin, B. M.,
Annu. Rev. Biochem
. 63:717-743 (1994)). Elongin (SIII) is a potential target for regulation by the product of the von Hippel-Lindau (VHL) tumor suppressor gene, which is mutated in the majority of clear-cell renal carcinomas and in families with VHL disease, a rare genetic disorder that predisposes individuals to a variety of cancers (Duan, D. R. et al.,
Science
269:1402-1406 (1995), Kibel, A. et al.,
Science
269:1444-1446 (1995)). The ELL gene on chromosome 19pl3.1 was originally isolated as a gene that undergoes frequent translocations with the
Drosophila trithorax
-like MLL gene on chromosome 11q23 in acute myeloid leukemia (Thirman, M. J. et al.,
Proc. Natl. Acad. Sci. U.S.A
. 91:12110-12114 (1994), Mitani, K. et al.,
Blood
85:2017-2024 (1995)).
This indicates that these proteins have an established, proven history as therapeutic targets. Clearly there is a need for identification and characterization of further related proteins which can play a role in preventing, ameliorating or correcting dysfunctions or diseases, including, but not limited to, AIDS and neoplastic disorders, among others.
SUMMARY OF THE INVENTION
In one aspect, the invention relates to ELL2 polypeptides and recombinant materials and methods for their production. Another aspect of the invention relates to methods for using such ELL2 polypeptides and polynucleotides. Such uses includes the treatment of neoplastic disorders, among others. In still another aspect, the invention relates to methods to identify agonists and antagonists using the materials provided by the invention, and treating conditions associated with ELL2 imbalance with the identified compounds. Yet another aspect of the invention relates to diagnostic assays for the detection of diseases associated with inappropriate ELL2 activity or levels and mutations in ELL2 that might lead to neoplastic disorders (particularly leukemias).
REFERENCES:
patent: WO 94/01548 (1994-01-01), None
NCBI Entrez, GenBank Report, Accession No. AA655966, from Marra, M. et al. (Nov. 1997), with Revision History.
NCBI Entrez, GenBank Report, Accession No. AA743118, from NCI-CGAP (Jan. 1998), with Revision History.
NCBI Entrez, GenBank Report, Accession No. W13766, from Marra, M. et al. (Oct. 1997), with Revision History.
NCBI Entrez, GenBank Report, Accession No. AA252607, from NCI-CGAP (Aug. 1997), with Revision History.
NCBI Entrez, GenBank Report, Accession No. AA243384, from NCI-CGAP (Aug. 1997), with Revision History.
NCBI Entrez, GenBank Report, Accession No. AA524290, from NCI-CGAP (Aug. 1997), with Revision History.
NCBI Entrez, GenBank Report, Accession No. AA375277, from Adams, M.D. et al. (Apr. 1997), with Revision History.
NCBI Entrez, GenBank Report, Accession No. AA009921, from Hillier, L. et al. (May 1997), with Revision History.
NCBI Entrez, GenBank Report, Accession No. AA545429, from Marra, M. et al. (Aug. 1997), with Revision History.
NCBI Entrez, GenBank Report, Accession No. AA414990, from Marra, M. et al. (May 1997), with Revision History.
NCBI Entrez, GenBank Report, Accession No. AA370180, from Adams, M.D. et al. (Apr. 1997), with Revision History.
NCBI Entrez, GenBank Report, Accession No. AA370048, from Adams, M.D. et al. (Apr. 1997), with Revision History.
NCBI Entrez, GenBank Report, Accession No. W92650, from Hillier, L. et al. (Nov. 1996), with Revision History.
NCBI Entrez, GenBank Report, Accession No. W94585, from Hillier, L. et al. (Nov. 1996), with Revision History.
NCBI Entrez, GenBank Report, Accession No. AA191245, from Hillier, L. et al. (Jan. 1997), with Revision History.
NCBI Entrez, GenBank Report, Accession No. R12663, from Hillier, L. et al. (1995), with Revision History.
NCBI Entrez, GenBank Report, Accession No. R16400, from Hillier, L. et al. (1995), with Revision History.
NCBI Entrez, GenBank Report, Accession No. N39822, from Hillier, L. et al. (Jan. 1996), with Revision History.
Yu, H. et al., “Structural Basis for the Binding of Proline-Rich Peptides to SH3 Domains,”Cell 76:933-945 (1994).
NCBI Entrez, GenBank Report, Accession No. Z20670, from MRC Human Genome Mapping Project Resource Centre (1995), with Revision History.
NCBI Entrez, GenBank Report, Accession No. T89063, from Hillier, L. et al. (1995), with Revision History.
Thirman, M.J. et al., “Cloning of ELL, a gene that fuses to MLL in a t(11;19)(q23;p13.1) in acute myeloid leukemia,”Proc. Natl. Acad. Sci. USA 91:12110-12114 (1994).
Willott, E. et al., “The tight junction protein ZO-1 is homologous to the Drosophila discs-large tumor suppressor protein of a septate junctions,”Proc. Natl. Acad. Sci. USA 90:7834-7838 (1993).
Woods, D.F. and P.J. Bryant, “The Discs-Large Tumor Suppressor Gene of Drosophila Encodes a Guanylate Kinase Homolog Localized at Septate Junctions,”Cell 66:451-464 (1991).
Shilatifard, A. et al., “An RNA Polymerase II Elongation Factor Encoded by the Human ELL Gene,”Science 271:1873-1876 (Mar. 1996).
Stark, M.J.R., “Multicopy expression vectors carrying the lac repressor gene for regulated high-level expression of genes inEscherichia coli,”Gene 51:255-267 (1987).
Tan, S. et al., “A Bacteriophage Vector Suitable for Site-Directed Mutagenesis and High-Level Expression of Multisubunit Proteins inE.coli,”BioTechniques 16:824-828 (1994).
Rice, G.A. et al., “Footprinting analysis of mammalian RNA polymerase II along its transcript: An alternative view of transcription elongation,”Proc. Natl. Acad. Sci. USA 88:4245-4249 (1991).
Ruff, P. et al., “Molecular identification of a major palmitoylated erythrocyte membrane protein containing the src homology 3 motif,”Proc. Natl. Acad. Sci. USA 88:6595-6599 (1991).
Shilatifard, A. et al., “ELL2, a new member of an ELL family of RNA polymerase II elongation factors,”Proc. Natl. Acad. Sci. USA 94:3639-3643 (Apr. 1997).
Price, D.H. et al., “Dynamic Interaction between a Drosophila Transcription Factor and RNA Polymerase II,”Mol. Cell. Biol. 9:1465-1475 (1989).
Reines, D., “Nascent RNA Cleavage by Transcription Elongation Complexes,” In:Transcription: Mechanisms and Regulation, Conaway, R.C. and J.W. Conaway, eds., Raven Press, Ltd., New York, NY, pp. 263-278 (1994).
Reines, D. et al., “The RNA polymerase II general elongation factors,”Trends in Biochemical Sci. (TiBS)21:351-355 (Sep. 1996).
Marshall, N.F. and D.H. Price, “Purification of P-TEFb, a Transcription Factor Required for the Transition into Productive Elongation,”J. Biol. Chem. 270:12335-12338 (1995).
Marshall, N.F. et al., “Control of RNA Polymerase II Elongation Potential by a Novel Carboxyl-terminal Domain Kinase,”J. Biol. Chem. 271:27176-27183 (Oct. 1996).
Mitani, K. et al., “Cloning of Several Species of MLL/MEN Chimeric cDN
Conaway Joan W.
Conaway Ronald C.
Duan D. Roxanne
Shilatifard Ali
Brusca John S.
Human Genome Sciences Inc.
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
ELL2, a new member of an ELL family of RNA polymerase II... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with ELL2, a new member of an ELL family of RNA polymerase II..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ELL2, a new member of an ELL family of RNA polymerase II... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2852703